Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
altSonflex1-2-3 Vaccine Against S. Sonnei and S. Flexneri in Adults, Children, and Infants
NCT05073003Phase 2Completed
- Sponsor
- GSK
- Start
- Oct 2021
- Primary completion
- Jun 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 2 trial of altSonflex1-2-3 in shigellosis, sponsored by GSK. Started Oct 2021; status: completed.
02
Drugs
altSonflex1-2-3
03
Conditions
shigellosis
Beyond the preview
Go deeper on NCT05073003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05073003.